{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-020128","form_type":"8-K","ticker":"BCPC","cik":"0000009326","company_name":"BALCHEM CORP","filed_at":"2024-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.540208+00:00","generated_at":"2026-06-02T23:40:12.435090+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Balchem reports record Q1 net sales of $239.7M, adjusted EBITDA up 8%","bullets":["Net sales $239.7M (+3.1% YoY), adjusted EBITDA $60.9M (+8.0% YoY), both all-time records.","GAAP EPS $0.89 vs $0.70; adjusted EPS $1.03 vs $0.94 in prior-year quarter.","Human Nutrition & Health segment sales $152.7M (+15.1%), earnings $33.3M (+80.4%).","Cash from operations $33.4M; free cash flow $26.8M for Q1 2024.","VitaCholine became Proud Partner of New York Jets, first sponsorship in nutritional ingredient category."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-020128","json":"https://secwatch.observer/filing/0001628280-24-020128.json","markdown":"https://secwatch.observer/filing/0001628280-24-020128.md","text":"https://secwatch.observer/filing/0001628280-24-020128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/9326/000162828024020128/0001628280-24-020128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/9326/000162828024020128/bcpc-20240503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:40:12.435090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a7cfb30aeb40a93ac5c0c25df153f941f7c5688","claim":"BALCHEM CORP reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 3, 2024, Balchem Corporation, reported earnings for the quarter ended March 31, 2024, and certain other information. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/9326/000162828024020128/0001628280-24-020128-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}